Hitto Kaufmann has been appointed chief scientific officer at Hansa Biopharma AB, effective 1 December. Hansa has developed enzyme technology or rare immunological conditions. Dr Kaufmann will be joining from Pieris Pharmaceuticals Inc where he was also CSO leading the development of protein therapeutics. Prior to this, he was an executive at Sanofi SA helping oversee industrial affairs and R&D. Dr Kaufmann received a PhD in natural science at the Swiss Federal Institute of Technology in Zurich, Switzerland.
Hansa Biopharma announced the appointment on 1 September 2024.
Copyright 2023 Evernow Publishing Ltd.